SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1625)9/14/2000 4:04:43 PM
From: Biomaven  Respond to of 52153
 
Thanks, Ice. I see now that the Maxamine 48 week numbers were a little worse than the 24 week numbers (61% undetectable at the higher doses vs. 69% in 24 week trial).

Of course it would likely be used in practice w/ a peg-interferon and ribavirin. We'll have to see how those trials go.

Certainly the prognosis for Hep C patients is looking up. There's VRTX and RZYM (and quite a few others) lying in wait as well.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News